Keytruda (pembrolizumab) is prescribed to treat melanoma and other conditions by reviving the body’s immune system. Your response to this drug may vary based on your medical history, diagnosis, and ...

Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements. Patients with advanced non-small cell lung cancer ...

Tracon Pharmaceuticals Inc. is shuttering all development of its subcutaneous PD-L1 antibody, envafolimab, after the pivotal trial failed to meet the primary endpoint in soft tissue sarcoma.

Therapeutic plasma exchange may allow patients with advanced melanoma to overcome immune checkpoint inhibitor resistance, data suggest.

Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard ...

Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo. Disease-free survival (DFS; time after diagnosis during which a person shows ...

Findings of the BEATcc trial suggest PD-L1 status is not a reliable biomarker for guiding immunotherapy selection in patients with recurrent or metastatic cervical cancer, potentially simplifying ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR 1 ...